Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope

LONDON, April 16, 2013 /PRNewswire/ --

Last year, patents on several blockbuster drugs expired, leading to increasing competition from generic drugs. The trend is expected to continue in 2013. In fact, rising competition from generic drugs is a major concern for drug manufacturers such as Amarin Corporation Plc (NASDAQ: AMRN), Pharmacyclics Inc. (NASDAQ: PCYC), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Start Scientific Inc. (NASDAQ: STSI), and Impax Laboratories Inc. (NASDAQ: IPXL). Shares of all five companies fell in Monday's trading session as the broad market saw its biggest one-day drop following the release of some disappointing economic data in the U.S. and China. StockCall has released full comprehensive research on AMRN, PCYC, ANTH, STSI, and IPXL and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Amarin Corporation Plc's shares were among the major losers in the healthcare sector yesterday. The stock fell to an intra-day low of $7.15 before finishing the day 5.63% lower at $7.21 on volume of 3.10 million. Amarin's shares have fallen nearly 10.90% so far in 2013, even as the broad market has posted significant gains. The stock is currently trading well below its 50-day and 200-day moving averages, which is a bearish signal. Free technical analysis on AMRN available by signing up at

http://www.StockCall.com/AMRN041613.pdf

Shares of Pharmacyclics Inc.'s shares fell sharply on Monday, extending their losses from previous trading sessions. The stock closed 3.87% lower at $72.51 on volume of 723,300, taking its losses in the last three sessions to nearly 6.50%. Despite the recent losses, the company's shares have gained nearly 25.50% thus far in the year. However, the stock has recently slipped below its 50-day moving average, which indicates that market sentiment has turned bearish on the stock. Register today and access the free research on PCYC at

http://www.StockCall.com/PCYC041613.pdf

Shares of Anthera Pharmaceuticals Inc. slipped yesterday. The stock closed 2.81% lower at $0.615 on volume of 711,400. Anthera's shares have fallen more than 3.10% in the last three trading sessions. the major drug maker's shares have traded sideways since February, struggling to break through $0.65 resistance level. The stock currently has strong support at around $0.60. Shares of ANTH are currently trading below their 50-day and 200-day moving averages, which is a bearish signal. The free report on ANTH can be downloaded by signing up now at

http://www.StockCall.com/ANTH041613.pdf

Star Scientific Inc. saw a huge selloff in Monday's trading session. Shares of the Glen Allen, Virginia-based company fell 8.78% to finish the day at $1.35 on volume of 1.57 million. The stock has fallen 10.6% in the last three sessions. Star Scientific's shares have seen a series of lows since the start of this year, which is a bearish signal. The stock has fallen nearly 50% so far in 2013. Free report on STSI can be accessed by registering at

http://www.StockCall.com/STSI041613.pdf

Shares of Impax Laboratories Inc. fell sharply on Monday. The stock ended the day 2.25% lower at $16.09 on volume of 706,900. Impax Laboratories' shares have fallen nearly 21.50% so far in 2013, compared to a gain of over 8.80% for the S&P 500. The stock is trading nearly 41% below its 52-week high. The company's shares are also trading below their 50-day and 200-day moving averages. Register with StockCall and download the research on IPXL for free at

http://www.StockCall.com/IPXL041613.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  

SOURCE StockCall.com

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.